

## **Chorus Community Health Plans**

Long-Acting and Short-Acting Opioid Analgesics Prior Authorization Form IF THIS IS AN URGENT REQUEST, please call Chorus Community Health Plans Pharmacy Services.						
Otherwise please return completed form to: Chorus Community Health Plans Pharmacy Services						
Phone: 844-201-4677 Fax: 844-201-4675						
<u>PLEASE TYPE OR PRINT NEATLY</u> Incomplete responses may delay this request.						
Office contact:			Provider specialty:			
Provider first name: Pro			Provider last i	Provider last name:		
Provider phone #:	Provider fax #:			Provider NPI #:		
Patient name:	CCHP Member ID #:			Patient DOB:	Patient age:	
Please provide member's weight (include units):						
Drug requested:	g requested: Strength: Freque		ncy:	cy: Quantity dispensed (including units):		
Brand Generic						
Generic equivalent drugs will be substituted for brand name drugs unless you specifically indicate otherwise.						
New medication Ongoing medication			d the member show Yes while on therapy? No			
Please indicate below the mem		nplete pa		10		
Medication Name	Medication Strength		gth	Medication Frequency		
Please complete the following for an INITIAL authorization request						
Please indicate the member's diagnosis/diagnoses:						
Is the requested medication being prescribed as part of palliative/end of life care?  Yes  No Please indicate anticipated duration of therapy:						
Please indicate plan for taper/discontinuation:						
Has the member previously tried and failed the following? If yes, please provide information below.						
<ul> <li>Medications</li> <li>Non-medication therapies (i.e. exercise therapy, physical therapy, behavioral therapy, cognitive therapy)</li> </ul>						
Medication/Therapy Name	Medication/Therapy Name			Response or reason for discontinuation		
For long-acting opioid requests, please provide rationale for using a long-acting agent:						
Will the member be monitored for ongoing opioid therapy?  UYes  No						
Will the member be using non-pharmacological and non-opioid therapies in combination with opioid treatment? □Yes □ No						
Please be sure to complete and include the 2 <sup>nd</sup> page of this form.						

Long-Acting and Short-Acting Opioid Analgesics Page 2					
Patient Name:	Patient ID Number:	Patient DOB:			
Please be sure to complete and include the 1 <sup>st</sup> page of this form.					
Was a pain assessment tool completed confirming severe pain for duration of 3 months?  DYes DNo					
Was the member assessed for potential risk for opioid related harm and have strategies been considered					
to prevent opioid-related harm (such as naloxone)?   Yes  No					
Has the member been educated on potential adverse effects including the risk of misuse, abuse, and					
Has the member been educated on known risks and the realistic benefits of therapy? □Yes □ No					
Did the member have a recent urine drug screen prior to starting therapy? □Yes □ No					
Has the member been assessed recently (i.e. within the past 60 days) for continued use of opioid therapy?   Yes  No					
	g a benzodiazepine and/or other chronic opi e for concurrent use or discontinuation/taper				
□ Taper/discontinuation plan:					
	on Drug Monitoring Program reviewed?				
Please complete the following for a REAUTHORIZATION request					
<b>Please provide documentation showing improved pain control and improved level of functioning.</b> Documentation enclosed: $\Box$ Yes $\Box$ No					
Please provide rationale for continued use or plan for taper/discontinuation.					
□ Continued use: □ Taper/discontinuation plan: _					
Will the member continue to be monitored for ongoing opioid therapy? □Yes □ No					
Will the member be using non-pharmacological and non-opioid therapies in combination with opioid treatment? □Yes □ No					
<b>Is the member being followed</b> □Yes □ No	for opioid-related adverse effects and warni	ng signs for overdose/opioid use disorder?			
Was the member assessed for potential risk for opioid related harm and have strategies been considered					
to prevent opioid-related harm (such as naloxone)?  UYes  No					
Has the member had a recent urine drug screen?  UYes  No					
Is the member currently taking a benzodiazepine and/or other chronic opioids? □Yes □ No If yes, please provide rationale for concurrent use or discontinuation/taper plan for benzodiazepines or other					
If yes, please provide rational chronic opioids:	e for concurrent use or discontinuation/taper	plan for benzodiazepines or other			
□ Taper/discontinuation plan: _					
<b>Was the Wisconsin Prescription Drug Monitoring Program reviewed?</b> DYes D No					
Please provide any additional information in the space below.					